Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
Top Cited Papers
Open Access
- 3 May 2009
- journal article
- research article
- Published by Springer Nature in Nature Genetics
- Vol. 41 (6) , 718-723
- https://doi.org/10.1038/ng.374
Abstract
John Maris and colleagues report results of a genome-wide association and replication study for aggressive neuroblastoma. They show that common variants in the BARD1 locus at 2q35 are strongly associated with the disease. We conducted a SNP-based genome-wide association study (GWAS) focused on the high-risk subset of neuroblastoma1. As our previous unbiased GWAS showed strong association of common 6p22 SNP alleles with aggressive neuroblastoma2, we restricted our analysis here to 397 high-risk cases compared to 2,043 controls. We detected new significant association of six SNPs at 2q35 within the BARD1 locus (Pallelic = 2.35 × 10−9–2.25 × 10−8). We confirmed each SNP association in a second series of 189 high-risk cases and 1,178 controls (Pallelic = 7.90 × 10−7–2.77 × 10−4). We also tested the two most significant SNPs (rs6435862, rs3768716) in two additional independent high-risk neuroblastoma case series, yielding combined allelic odds ratios of 1.68 each (P = 8.65 × 10−18 and 2.74 × 10−16, respectively). We also found significant association with known BARD1 nonsynonymous SNPs. These data show that common variation in BARD1 contributes to the etiology of the aggressive and most clinically relevant subset of human neuroblastoma.Keywords
This publication has 19 references indexed in Scilit:
- The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case–control and family analysisBreast Cancer Research and Treatment, 2008
- NeuroblastomaPublished by Elsevier ,2007
- A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancerNature Genetics, 2007
- The BARD1 Cys557Ser Variant and Breast Cancer Risk in IcelandPLoS Medicine, 2006
- SNP-SNP interactions in breast cancer susceptibilityBMC Cancer, 2006
- Is there more to BARD1 than BRCA1?Nature Reviews Cancer, 2006
- BARD1 variants Cys557Ser and Val507Met in breast cancer predispositionEuropean Journal of Human Genetics, 2005
- Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trialThe Lancet Oncology, 2005
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999